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Abstract
Background: Macrolide antibiotics are commonly administered for bacterial respiratory illnesses. Azithromycin (Az) is 
especially noted for extremely high intracellular concentrations achieved within macrophages which is far greater than 
the serum concentration. Clinical strains of Type B Francisella (F.) tularensis have been reported to be resistant to Az, 
however our laboratory Francisella strains were found to be sensitive. We hypothesized that different strains/species of 
Francisella (including Type A) may have different susceptibilities to Az, a widely used and well-tolerated antibiotic.
Results: In vitro susceptibility testing of Az confirmed that F. tularensis subsp. holarctica Live Vaccine Strain (LVS) (Type B) 
was not sensitive while F. philomiragia, F. novicida, and Type A F. tularensis (NIH B38 and Schu S4 strain) were susceptible. 
In J774A.1 mouse macrophage cells infected with F. philomiragia, F. novicida, and F. tularensis LVS, 5 μg/ml Az applied 
extracellularly eliminated intracellular Francisella infections. A concentration of 25 μg/ml Az was required for Francisella-
infected A549 human lung epithelial cells, suggesting that macrophages are more effective at concentrating Az than 
epithelial cells. Mutants of RND efflux components (tolC and ftlC) in F. novicida demonstrated less sensitivity to Az by 
MIC than the parental strain, but the tolC disc-inhibition assay demonstrated increased sensitivity, indicating a complex 
role for the outer-membrane transporter. Mutants of acrA and acrB mutants were less sensitive to Az than the parental 
strain, suggesting that AcrAB is not critical for the efflux of Az in F. novicida. In contrast, F. tularensis Schu S4 mutants 
ΔacrB and ΔacrA were more sensitive than the parental strain, indicating that the AcrAB may be important for Az efflux 
in F. tularensis Schu S4. F. novicida LPS O-antigen mutants (wbtN, wbtE, wbtQ and wbtA) were found to be less sensitive in 
vitro to Az compared to the wild-type. Az treatment prolonged the survival of Galleria (G.) mellonella infected with 
Francisella.
Conclusion: These studies demonstrate that Type A Francisella strains, as well as F. novicida and F. philomiragia, are 
sensitive to Az in vitro. Francisella LPS and the RND efflux pump may play a role in Az sensitivity. Az also has 
antimicrobial activity against intracellular Francisella, suggesting that the intracellular concentration of Az is high 
enough to be effective against multiple strains/species of Francisella, especially in macrophages. Az treatment 
prolonged survival an in vivo model of Francisella-infection.
Background
Bacteria in the Francisella genus are nonmotile, nonspo-
rulating, gram-negative coccobacilli. Francisella causes a
zoonotic disease; humans can become infected via a vari-
ety of mechanisms including inhalation of an extremely
low infectious dose [1]. F. tularensis primarily targets
macrophages where bacterial survival and replication
occurs [1]. The genus Francisella is divided into two spe-
cies:  tularensis  and  philomiragia.  Francisella tularensis
has four subspecies: F. tularensis subspecies  tularensis
(formerly F. tularensis,) F. tularensis subspecies holarctica
(which includes the live vaccine strain, LVS), F. tularensis
subspecies  mediasiatica, and F. tularensis subspecies
novicida (F. novicida) [2]. Subspecies of Francisella tular-
ensis are further separated into two types depending on
their virulence. Type A strains include Francisella tular-
ensis subspecies tularensis Schu S4 (F. tularensis Schu S4)
and are more virulent [3], except for the ATCC type
strain F. tularensis subsp. tularensis NIH B38 which is
avirulent [4-6]. Francisella Type A strains are normally
associated with ticks and rabbits and are restricted to
North America. Type B strains (Francisella tularensis
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subspecies holarctica and mediasiatica) are less virulent
and cause tularemia throughout Eurasia [3].
Standard recommended antibiotic treatment for tulare-
mia includes oral tetracycline antibiotics (e.g. doxycy-
cline) and fluoroquinolones (e.g. ciprofloxacin) which
have adverse side-effects on pediatric and the elderly
patients, and individuals with liver disease. Aminoglyco-
sides such as streptomycin and gentamicin can be
injected intravenously or intramuscularly [7], but are not
commonly used. Macrolides are oral antibiotics com-
monly used to treat bacterial respiratory illnesses.
Azithromycin (Az), a member of the azalide subclass of
macrolides, binds to the 50 s subunit of gram-negative
bacterial ribosomes, and inhibits translation of mRNA
resulting in inhibition of bacterial growth or death [8]. It
has been suggested that the two basic amine sites of Az
interact with the negatively charged heptose-phosphate
region of lipopolysaccharide (LPS) in order to enter
gram-negative bacteria [9]. F. novicida transposon inser-
tion mutants in the genes involved in lipopolysaccharide
(LPS) production (wbtN, wbtE, wbtQ and  wbtA) were
tested to determine if there might be a role of LPS in Az
binding and penetration. Mutations in genes responsible
for the synthesis of the O-antigen in F. novicida have been
previously shown to decrease virulence and resistance to
serum killing while macrophage uptake and replication
remained unaffected [10].
A primary mode of bacterial resistance to antibacterial
drugs is the expression of drug efflux pumps such as
ATP-binding cassette (ABC), the Major Facilitator Super-
family (MFS) transporters, and Resistance-Nodulation-
Division (RND) efflux system. These inner membrane
transport systems are often coupled to the outer mem-
brane TolC system [11]. Francisella novicida has two
tolC-like proteins, tolC and the highly related fltC [12].
The ABC Superfamily is thought to be responsible for the
export of many different antibiotics. For example, in E.
coli, macrolides are thought to be transported by the ABC
transporter MacAB [13]. Although a potential macA gene
was identified in F. novicida (FTN_1692), no gene corre-
sponding to macB could be identified in the F. novicida
genome. The RND efflux system consists of a tripartite
transporter with an RND pump protein located in the
cytoplasmic membrane (AcrB) and a periplasmic mem-
brane fusion protein (AcrA) coupled to the TolC protein
in the outer membrane (Figure 1). The RND system can
pump many compounds, including macrolides [14]. The
AcrAB RND efflux pump was recently demonstrated to
be required for F. tularensis LVS virulence in mice [15],
but not in F. tularensis Schu S4 [16]. The function of the
RND efflux system is the removal of harmful substances
from inside the cytosol of the bacteria directly to the
external medium bypassing the periplasm [15]. Thus we
hypothesized that mutants in the RND efflux system
would have altered sensitivity to Az. Transposon inser-
tion mutants of components of the RND efflux system in
F. novicida, including tolC, fltC, acrA, and acrB, were
tested for their sensitivity to Az. The dsbB gene encodes
the cytoplasmic membrane protein that is involved in dis-
ulfide bond formation in the periplasm. A dsbB mutant in
F. novicida was tested because it is transcriptionally
linked in an operon with acrA and acrB in Francisella.
Mutants ΔacrA and ΔacrB were also tested in the fully
virulent strain, F. tularensis Schu S4 [16].
Az, which is commonly prescribed to pediatric patients
for treatment of common upper respiratory track and ear
infections [17], has low toxicity and few side-effects [18].
When administered, the antibiotic becomes ion-trapped
in the acidic lysosomes of white blood cells including
macrophages resulting in a high intracellular concentra-
t i o n  c o m p a r e d  t o  t h e  p l a s m a  d u r i n g  t h e  d o s e  p e r i o d .
Intracellular concentrations remain high after the dose
period ends with a half-life of 68 hours [18].
Murine macrophages J774A.1 are a well-studied in
vitro model system for tularemia [19,20] and were chosen
as a model cell system to study Francisella infection and
treatment by Az. The murine macrophage cell line
J774A.1 supports the intracellular replication of F. tular-
ensis LVS [19], F. novicida [21], and F. tularensis Schu S4
[16]. For a model of the human system, human lung epi-
thelial cells A549 were chosen. F. tularensis LVS has been
previously shown to infect and replicate within A549 cells
[22-24]. We hypothesized that the ability of Az to concen-
trate at high levels within the macrophages may result in
effectiveness against intracellular infections by Franci-
sella species, even at extracellular Az levels lower than
the MIC.
The larval stage of Galleria (G.)mellonella, wax moth
caterpillar, has been used as a model to study infections
caused by some bacteria including F. tularensis LVS [25].
The larvae do not have an adaptive immune system, but
have resistance to microbial infections via cellular and
humoral defenses [26]. The analysis of insect responses to
Figure 1 RND efflux pump. A schematic of the RND efflux pump, fol-
lowing [59], to illustrate the relationship between TolC, AcrA and AcrB.
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pathogens can provide an accurate indication of the
mammalian response to that pathogen. Physical effects
such as color change can be observed when the bacteria
replicates and increases in the larvae [25]. We used G.
mellonella as an alternative to the mouse model of Fran-
cisella infection to test our hypothesis that Az treatment
could prolong the survival of Francisella infected cater-
pillars.
Results
Francisella's sensitivity to Az
I t  h a s  b e e n  r e p o r t e d  t h a t  E u r o p e a n  c l i n i c a l  s t r a i n s  o f
Type B F. tularensis are resistant to Az [27]. However, we
observed that commonly used laboratory strains of Fran-
cisella are sensitive to Az. In vitro susceptibility testing of
Az confirmed that F. tularensis LVS strain was not highly
sensitive in vitro to this antibiotic, confirming that the
Type B strains are relatively resistant to this antibiotic.
Our study demonstrated that F. philomiragia, F. novicida
and Type A F. tularensis tularensis, including both F. tula-
rensis tularensis NIH B38 and F. tularensis Schu S4
strains, were susceptible to this drug in vitro and in vivo.
Francisella  strains were tested in a Kirby-Bauer disc
inhibition assay for sensitivity to Az. F. novicida, F. philo-
miragia, and F. tularensis tularensis B38 were sensitive to
15 μg Az discs, whereas F. tularensis LVS was not sensi-
tive to this concentration. F. novicida had a zone of inhi-
bition of 28.7 ± 0.7 mm in diameter around the 6 mm Az
disc, and F. philomiragia's zone of inhibition was 21.7 ±
0.8 mm in diameter. F. tularensis tularensis NIH B38 had
the largest zone of inhibition, 45.9 ± 6.2 mm in diameter
around the Az disc (Table 1). These results were all signif-
icantly different than F. tularensis LVS (p-value < 0.001).
Although F. tularensis tularensis NIH B38 is not virulent,
this result suggested the potential sensitivity of the Type
A strains to Az. In order to corroborate this with the fully
virulent strain, F. tularensis Schu S4 was tested and deter-
mined to have a zone of inhibition of 25.5 ± 1.9 mm (p-
value < 0.001 compared to F. tularensis LVS).
The Minimal Inhibitory Concentrations (MIC) for Az
and gentamicin were measured in liquid broth assays to
determine Francisella sensitivity to Az compared to con-
trol antibiotic gentamicin. F. novicida and F. philomiragia
were more susceptible to Az than F. tularensis LVS, which
was only susceptible to Az at higher concentrations. The
MIC of Az for F. novicida is 0.78 μg/ml (EC50 of 0.16 μg/
ml), and 1.56 μg/ml (EC50 of 0.13 μg/ml) for F. philomira-
gia. These results were all significantly different than F.
tularensis LVS (MIC of 25.0 μg/ml; EC50 of 17.3 μg/ml; p-
value ≤ 0.004) (Figure 2, Table 2). The MIC result for F.
tularensis LVS explains why there was no inhibition of
growth in the disc-diffusion assay, as there was only 15 μg
of Az in the disc, which is below the MIC and the EC50.
Our studies were performed with Francisella LVS strain
NR-646 from BEI Resources, who state that it has been
confirmed by PCR amplification of a sub-species specific
sequence to be subsp. holarctica (Type B). Our results
differ from those reported by Ikaheimo et al. for the Type
B ATCC 29684, deposited in BEI as Francisella LVS NR-
14, who reported a MIC for azithromycin of >256 mg/L
[27]. Results for F. tularensis Schu S4 were similar to F.
novicida with a MIC of 0.78 μg/ml, and EC50 of 0.15 μg/
ml Az (Table 2). This is consistent with the disc inhibition
assay results. These results are also similar to results with
related macrolide antibiotic, erythromycin, which has a
reported MIC of 0.5-4, and EC50 of 2 μg/ml against Type
A and B Francisella strains, though not LVS (MIC > 256
μg/ml) [28]. As a control, we determined the MIC for the
antibiotic gentamicin to which all strains of Francisella
are susceptible [29]. The MIC of gentamicin for F. novi-
cida was determined to be 0.2 μg/ml (EC50 of 0.12 μg/ml);
for F. philomiragia the MIC was 0.39 μg/ml (EC50 of 0.22
μg/ml); and for F. tularensis LVS the MIC was 0.39 μg/ml
Table 1: Az Disk Inhibition Assay with Francisella strains.
Bacterial Strains Antibiotic Zone of Inhibition (mm) (Disc is 6 mm) p-value
F. tularensis LVS 6.0 ± 0 ----
F. novicida 28.7 ± 0.7 <0.001
F. philomiragia 21.7 ± 0.8 <0.001
F. tularensis NIH B38 45.9 ± 6.2 <0.001
F. tularensis Schu S4 25.5 ± 1.9 <0.001
15 μg Az discs (Fluka) were placed on the agar and the zone of inhibition was measured. P-value was calculated compared to F. tularensis LVS.Ahmad et al. BMC Microbiology 2010, 10:123
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(EC50 of 0.09 μg/ml) (Table 2). These values are consistent
with published sensitivities of Type B strains (MIC of
0.03-0.5 μg/ml, EC50 of 0.12 μg/ml) [28]. Thus, the Type A
Francisella tularensis SchuS4, F. novicida and F. philomi-
ragia are all sensitive to Az in vitro. Type B Francisella
LVS was also determined to be sensitive, but at a higher
concentration of Az.
J774A.1 and A549 cells were infected with Francisella
and treated with Az. The same multiplicity of infection
(MOI = 500) was used, based on previous studies for
Francisella infection [30]. Cells were lysed and bacteria
were recovered and counted as colony forming units
(CFU). Francisella-infected J774A.1 and A549 cells were
found to have more than 105 CFU/ml of Francisella after
22 hours after infection. J774A.1 cells infected with Fran-
cisella and treated with Az had decreasing CFUs as the
antibiotic concentration increased. In J774A.1 cells
infected with F. philomiragia, no CFUs were recovered
when treated with 0.1 μg/ml Az (less than the MIC). In
J774A.1 cells infected with either F. novicida or F. tularen-
sis LVS, bacterial concentrations decreased with the addi-
tion of Az. At 5 μg/ml Az, no CFUs were recovered (p-
value < 0.005 compared to 0 μg/ml Az) (Figure 3A). In
this case, the Az concentration was less than the MIC for
F. tularensis LVS. Francisella-infected A549 cells required
higher concentrations of Az than J774A.1 cells, suggest-
ing that epithelial cells are not able to concentrate Az in
the same manner as macrophages. As before, intracellular
F. novicida, F. philomiragia, and F. tularensis LVS CFU
counts decreased when A549 cells were treated with Az.
Recovered intracellular CFU counts for F. philomiragia
and F. novicida remained approximately equal when
treated with 0.1 and 5 μg/ml Az (p-value > 0.05), but
strongly decreased at 25 μg/ml Az (p-value < 0.005 com-
pared to 0 μg/ml Az). For these two organisms, the
required external antibiotic concentration was higher
than the in vitro MIC. F. tularensis LVS infected A549
cells had a steady decline of intracellular CFU counts as
the Az concentration increased and had essentially no
colonies recovered at 25 μg/ml extracellular Az (p-value <
0.005 compared to 0 μg/ml Az), which is equivalent to the
MIC for that strain (Figure 3B). The difference between
the cell types may reflect the fact that J774A.1 cells are
phagocytic macrophages, and the A549 cells are non-
phagocytic epithelial cells.
To determine if Francisella  bacteria counts were
decreased due to Az concentrations or due to cell death,
cellular lysis and apoptosis were measured by LDH
released [19]. At 22 hours, cell cytotoxicity in non-
infected A549 cells and A549 cells infected with F. novi-
cida, F. philomiragia, and F. tularensis LVS remained
below 20%. Non-infected A549 cells along with F. philo-
miragia, F. novicida, and F. tularensis LVS-infected cells
had a slightly increased cytotoxicity as Az concentrations
increased (Table 3). Cellular apoptosis remained low with
all Az doses. These results suggest the decreased Franci-
Table 2: MIC Assay of Az for Francisella strains.
Bacteria Az MIC (μg/ml) Az EC50(μg/ml) p-value Gent MIC (μg/ml) Gent EC50(μg/ml)
F. tularensis LVS 25 17.34 ---- 0.39 0.09
F. philomiragia 1.56 0.13 <0.001 0.39 0.22
F. novicida 0.78 0.16 <0.001 0.20 0.12
F. tularensis Schu S4 0.78 0.1453 0.004 n/a n/a
The p-value is for comparisons of the EC50 values.
Figure 2 MIC determination of Az for F. tularensis LVS, F. philomi-
ragia, F. novicida, and F.tularensis Schu S4. Az MIC for F. tularensis 
LVS (circles) is higher than F. philomiragia (squares), F. novicida (up tri-
angle), and F. tularensis Schu S4 (down triangle). Az MICs for F. novicida 
and F. tularensis Schu S4 are 0.78 μg/ml with an EC50 of 0.16 μg/ml and 
0.15 μg/ml respectively. F. philomiragia's Az MIC is 1.56 μg/ml with an 
EC50 of 0.13 μg/ml, and F. tularensis LVS's Az MIC is 25 μg/ml with an 
EC50 of 17.34 μg/ml.
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sella counts were due to Az treatment and not due to bac-
terial release during the experiment from apoptosis or
cell lysis.
Francisella LPS mutants
Due to the potential for interaction of Az with LPS [9],
four F. novicida transposon LPS O-antigen mutants were
tested for their Az susceptibility: O-antigen of LPS (wbtA)
biosynthesis of GdNAcAN, an O-antigen unit (wbtE), gly-
cosylatransferase that elongates to form GalNAcAN tri-
saccharides (wbtQ), and aminotransferase (wbtN) [10]. F.
novicida LPS O-antigen mutants including wbtA, wbtE,
wbtQ, and wbtN were shown to be less susceptible to Az
by decreased zones of inhibition in comparison to the
wild-type (p-value < 0.001) (Table 4). The MICs for Az
against the F. novicida LPS-related transposon mutants
wbtA, wbtE, wbtQ, and wbtN (MIC's > 3.0 μg/ml Az, EC50
> 0.50 μg/ml Az) were greater than the wild-type MIC
(0.78 μg/ml) (p-value < 0.005) (Figure 4A, Table 5), sug-
gesting increased resistance to Az. These data are consis-
tent with the disc inhibition studies, suggesting that
Francisella LPS plays some role in the sensitivity of the
strains for Az.
Francisella RND mutants
Five F. novicida transposon insertion mutants in the mul-
tidrug efflux protein genes (acrA and acrB), the transcrip-
tionally linked protein gene (dsbB), as well as the related
outer membrane channel genes (tolC  and  ftlC) were
tested to determine if Az susceptibility increases or
decreases [12]. Results for the RND efflux mutants varied
among the different subspecies (Table 6). In the disc inhi-
bition assay, the tolC mutant was slightly more sensitive
to Az compared to the wild-type F. novicida (p-value =
0.007), while ftlC, acrA, and acrB were less susceptible to
Az compared to the wild-type (p-value < 0.01) (Table 6).
The MICs for ftlC, tolC, acrA, and acrB (MIC = 25 μg/ml
Az) were greater than the wild-type (MIC of 0.78 μg/ml
Az) and had a higher EC50 (EC50 > 12 μg/ml Az) com-
pared to the wild-type of 0.16 μg/ml Az (p-value < 0.002),
indicating decreased sensitivity to the antibiotic. These
results are consistent between the MIC and disc inhibi-
tion assay for acrA, acrB, and ftlC (Figure 4B, Table 5).
The tolC sensitivity to Az results in the solid agar and liq-
uid broth assay were inconsistent. The disc-inhibition
assay suggests increased sensitivity, while the MIC assay
demonstrated increased resistance. We are currently
investigating the basis of this difference.
In the disc inhibition assay of the disulfide bond protein
mutant  dsbB, there was no significant difference com-
pared to the wild-type (p-value = 0.162) (Table 6). Simi-
larly, the MIC for dsbB  was not significantly different
than the wild-type value (p-value = 0.400) (Table 5).
Thus, mutation of dsbB does not seem to have a signifi-
cant impact on the ability of the organism to resist Az,
whereas transposon insertion mutants in the tolC, ftlC,
acrA  and  acrB  components of the RND efflux system
appear to decrease the sensitivity of F. novicida to Az.
This result for tolC and ftlC may be in contrast to Gil et al.
[12], who found that F. tularensis LVS deletion of tolC or
ftlC did not alter the sensitivity to erythromycin (15 μg
disc). The MIC of F. tularensis LVS is higher than can be
achieved using a 15 μg disc, reported at >256 μg/ml
erythromycin [28]. Therefore, any alteration in sensitivity
due to tolC deletion would not be observed at this low
concentration of antibiotic.
In contrast to the F. novicida results, the F. tularensis
Schu S4 ΔacrA mutant and ΔacrB mutants had greater
sensitivity to Az compared to the wild-type F. tularensis
Figure 3 Az inhibition of intracellular Francisella strains. After 22 
hours, recovered bacterial counts were measured for F. philomiragia, F. 
novicida, and F. tularensis LVS infected cells (MOI 500). A) J774A.1 cells 
infected with F. philomiragia, F. novicida, or F. tularensis LVS had more 
than 105 CFU/ml. Bacterial counts decreased for all strains as the Az 
concentrations increased and were near 0 CFU/ml at 5 μg/ml Az. B) 
A549 cells infected with F. philomiragia, F. novicida, or F. tularensis LVS 
had more than 105 CFU/ml at 0 μg/ml Az. Bacterial counts decreased 
at 0.1 and 5 μg/ml Az and were near 0 CFU/ml at 25 μg/ml Az. CFU 
counts from no Az treatment compared 0.1, 5, and 25 μg/ml Az treat-
ment for all Francisella strains were significantly different (p-value < 
0.005).
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Schu S4 (p-value < 0.001) (Table 6). This is consistent
with the findings of Qin et al. [16] who found an
increased sensitivity of ΔacrB to 50 μg disc erythromycin.
The MICs for Az against F. tularensis Schu S4 RND efflux
mutants were also determined. The MICs for ΔacrA and
ΔacrB (MIC > 1.5 μg/ml Az) are higher than the wild-
type MIC of 0.78 μg/ml Az (p-value < 0.02) (Figure 4C,
Table 5). However, the F. tularensis Schu S4 mutants for
ΔacrA (EC50 of 0.085 μg/ml) and ΔacrB (EC50 0f 0.049 μg/
ml) have EC50s less than the wild-type F. tularensis Schu
S4 (EC50 of 0.145 μg/ml), reflecting the altered shape of
the MIC curve and indicating increased sensitivity. Only
ΔacrB  was statistically significantly different for EC50
when compared to the wild-type F. tularensis Schu S4 (p-
value < 0.05). Thus, F. tularensis Schu S4 ΔacrA  and
ΔacrB mutants had greater sensitivity to Az compared to
F. novicida mutants, or the parental F. tularensis Schu S4
strain by disc inhibition assay and MIC.
Az inhibition of intracellular Francisella mutant strains
J774A.1 and A549 cells infected with F. novicida transpo-
son LPS mutant wbtA and multidrug efflux mutants ftlC,
tolC, acrA, and acrB had more than 104 CFU/ml 22 hours
post-infection (Figure 5). ftlC generally had lower CFU
counts, whereas the acrA  and  acrB  had higher CFU
counts in both cell lines. The CFU of F. novicida transpo-
son mutants decreased as the Az concentration increased
for each cell line (p-value < 0.005 for each Az treatment
compared to 0 μg/ml Az). At 35 μg/ml Az treatment, the
bacterial CFU count was near 0 CFU/ml in J774A.1 and
A549 cells (Figure 5). Thus, wbtA and the RND mutants
are capable of replication within J774A.1 and A549 cells,
although the overall number of bacteria per cell was
lower than for the parental F. novicida infection (1.76 ×
105 ± 6.36 × 103 CFU/ml in J774A.1 and 1.80 × 105 ± 1.41
× 104 CFU/ml in A549 cells at 0 μg/ml). Mutant trends
after Az treatments were significantly different from the
wild-type  F. novicida with a p-value < 0.05 (wild-type
decreased to 0 CFU/ml at 5 μg/ml Az in J774A.1 cells and
decreased to 0 CFU/ml at 25 μg/ml Az in A549 cells).
Corresponding to the higher MICs identified in vitro, LPS
mutants require more Az to eliminate the bacteria from
infected cells.
Table 3: A549 cell cytotoxicity.
Bacteria 0 μg/ml Az 0.1 μg/ml Az 1.0 μg/ml Az 2.5 μg/ml Az 5.0 μg/ml Az
A549 cells 0 ± 3.0 2.9 ± 2.8 8.0 ± 4.0 18.3 ± 5.2 19.7 ± 9.6
F. novicida 0 ± 2.3 4.1 ± 5.0 3.3 ± 6.3 9.6 ± 5.4 17.8 ± 13.2
F. philomiragia 0 ± 1.3 0 ± 2.5 7.1 ± 4.6 1.7 ± 3.2 8.5 ± 4.1
F. tularensis LVS 0 ± 3.7 2.12 ± 5.0 4.6 ± 5.9 8.4 ± 5.1 5.2 ± 5.6
Using a LDH release assay, the cell cytotoxicity as a result of antibiotic and/or Francisella infection was determined and is indicated as a 
percentage (%) of total LDH released.
Table 4: Az Disk Inhibition Assay with Francisella transposon mutants of LPS production genes.
Antibiotic No Growth Zone (mm)
F. novicida Avg P-value
wild-type 28.7 ± 0.7 -------
wbtA 20.8 ± 0.5 <0.001
wbtN 23.3 ± 0 <0.001
wbtE 23.0 ± 0.9 <0.001
wbtQ 20.1 ± 1.3 <0.001
15 ug Az discs from Fluka were placed on an agar plate spread with the indicated strain. The zone of inhibition was measured in mm.Ahmad et al. BMC Microbiology 2010, 10:123
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G. mellonella infection by Francisella and antibiotic 
treatment
Francisella-infected G. mellonella was used as a model
system [25] to study Az treatment. G. mellonella were
infected with either 3 × 106 CFU bacteria/larva of F. novi-
cida or F. tularensis LVS and then treated with a single
dose of 10 μl injections PBS (no antibiotic), 20 μg/ml cip-
rofloxacin, or 25 μg/ml Az. Control groups (no infection)
consisted of no injections, injections of either PBS (to
measure trauma related to injections), 20 μg/ml cipro-
floxacin, or 25 μg/ml Az (to assess antimicrobial agent
effects on the host). All controls had similar survival rates
(data not shown for antibiotic injection only controls).
Francisella-infected  G. mellonella did not survive past
100 hours post-infection. Control groups survived for
more than 300 hours. Infected groups treated with a sin-
gle dose 20 μg/ml ciprofloxacin (mean time to death > 74
hours) or 25 μg/ml Az (mean time to death > 160 hours)
had a statistically significant prolonged survival times
when compared to infected groups (p-value < 0.005) (Fig-
ure 6A &6B). These results are consistent with previously
published results of G. mellonella infected with F. tular-
ensis LVS and treated with 20 μg/ml ciprofloxacin [25].
Although we could not achieve complete recovery, Fran-
cisella-infected G. mellonella groups treated with Az had
an increased mean survival time compared to ciprofloxa-
cin-treated caterpillars (p-value < 0.02).
Discussion
The macrolide erythromycin has limited efficacy against
many gram-negative bacteria due to its hydrophobic
nature and lack of permeability of the gram-negative
outer membrane [31]. The sensitivity of erythromycin
varies between Francisella strains. In the North Ameri-
can Type A Francisella strains, erythromycin MICs range
from 0.5 to 4 μg/ml, while F. tularensis LVS has an MIC >
256 μg/ml [32]. The macrolide azithromycin is more
effective against gram-negative bacteria than erythromy-
cin [33]. Despite reports that European clinical strains of
Type B F. tularensis are resistant to Az (MIC > 256 mg/L)
[27], we observed that commonly used laboratory strains
were sensitive to Az. In this study, we have demonstrated
Table 5: MIC Assay of Az for F. novicida transposon mutants.
Bacteria AZ MIC (μg/ml) AZ EC50(μg/ml) p-value
F. novicida 0.78 0.16 ------
wbtQ 3.12 0.52 0.005
wbtN 12.5 0.54 <0.002
wbtE 25 0.50 <0.001
wbtA 12.5 0.67 0.007
dsbB 1.56 0.16 0.401
ftlC 25 13.47 <0.002
tolC 50 16.44 <0.001
acrA 50 12.39 <0.001
acrB 50 13.23 0.001
F. tularensis Schu S4 0.78 0.1453 -------
ΔacrA 3.13 0.0852 0.087
ΔacrB 1.56 0.0493 0.031
MIC and EC50 were calculated as described. p-values compare the EC50 of mutants to wild-type F. novicida and F. tularensis Schu S4.Ahmad et al. BMC Microbiology 2010, 10:123
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Figure 4 MIC determination of Az for F. novicida transposon LPS and RND efflux mutants and F. tularensis Schu S4 RND efflux mutants. A) 
The MIC of Az for LPS O-antigen F. novicida transposon mutants was generally higher than the wild-type (circle) MIC of 0.78 μg/ml. MICs for LPS O-
antigen mutants were 12.5 μg/ml for wbtA (diamond), 25.0 μg/ml for wbtE (down triangle), 3.12 μg/ml for wbtQ (square), and 12.5 μg/ml for wbtN 
(triangle), with an EC50 for all LPS O-antigen mutants greater than 0.50 μg/ml (p-value < 0.005). B) MICs for F. novicida transposon-insertion RND efflux 
mutant varied: dsbB (down triangle) was closer to the wild-type (closed circle) at 1.56 μg/ml (p-value 0.400). ftlC, tolC, acrA, and acrB have greater MIC 
with 25 μg/ml for ftlC (square) and 50 μg/ml for tolC (up triangle), acrA (diamond), and acrB (open circle), with EC50 greater than 12 μg/ml (p-value < 
0.005). C) The MICs of Az for F. tularensis Schu S4 (square) and deletion RND efflux mutants. F. tularensis Schu S4 (square) has an MIC of 0.78 μg/ml, 
ΔacrB (circle) of 1.56 μg/ml, and ΔacrA (diamond) of 3.13 μg/ml. F. tularensis Schu S4 and mutants all have EC50 less than 0.15 μg/ml (p-value < 0.1 for 
ΔacrA and ΔacrB compared to wild-type).
 Ahmad et al. BMC Microbiology 2010, 10:123
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that the Type A F. tularensis tularensis strains are sensi-
tive to Az in vitro. F. philomiragia and F. novicida are also
sensitive with similar MICs. We determined that the MIC
for F. tularensis LVS (NR-646) was 25 ug/ml Az, confirm-
ing the finding that LVS is relatively more resistant to Az
than other Francisella strains.
Az is pumped out of gram-negative bacteria by several
drug-efflux systems, including the RND efflux pumps. Az
sensitivity differed between F. novicida and F. tularensis
Schu S4 RND efflux mutants. Wild-type F. tularensis
Schu S4 has similar sensitivity to Az as wild-type F. novi-
cida, but the RND efflux mutants ΔacrA and ΔacrB in F.
tularensis Schu S4 are more sensitive to Az, whereas the
F. novicida acrA and acrB  mutants are more resistant.
These F. tularensis Schu S4 ΔacrA and ΔacrB mutants
were also reported to be more sensitive to the related
antibiotic erythromycin [16]. The difference between the
F. tularensis Schu S4 and the F. novicida mutants might
be due to the fact that F. tularensis Schu S4 has 254
pseudogenes; many of these genes are intact in F. novicida
[34]. For example, in F. tularensis Schu S4, at least 14
genes of the MFS transporter superfamily contain stop
codons or frameshifts [34,35] and are thus predicted to be
non-functional. Additional types of transporter proteins,
including a drug-resistance transporter (FTT1618), are
also reported to be non-functional pseudogenes [34] in F.
tularensis Schu S4. It could be that the remaining TolC-
AcrAB pump is the major means by which F. tularensis
Schu S4 pumps out Az. If this pump is compromised, the
organism would be more susceptible to the antibiotic,
because it may not have an operational alternative pump,
such as the MFS or ABC transporters to pump out the
drug. This is supported by the finding that ΔacrA and
ΔacrB  mutants in F. tularensis Schu S4 also displayed
increased sensitivity to nalidixic acid (a substrate for the
MFS transporter), as well as detergents, streptomycin,
tetracycline, and other molecules [16]. In the case of F.
novicida, there may be alternate systems that can pump
out the drug in the absence of the RND system. Alterna-
tively, the mutation in acrA or acrB may cause an up-reg-
ulation of expression of another drug-efflux pump,
rendering the bacteria more resistant to the antibiotic
[36,37]. Previous studies have shown that dsbB mutant in
F. tularensis Schu S4 does not have any effect on antibi-
otic sensitivity (including the macrolide erythromycin)
[16]. Consistent with the F. tularensis Schu S4 dsbB
mutant, the F. novicida dsbB mutant showed no differ-
ence from the wild-type F. novicida.
Table 6: Az Disk Inhibition Assay with Francisella transposon RND Efflux mutants.
Antibiotic No Growth Zone (mm)
F. novicida Avg p-value
wild-type 31.4 ± 1.0
ftlC 28.0 ± 3.1 0.006
tolC 33.2 ± 1.4 0.007
dsbB 30.7 ± 1.2 0.162
acrA 23.5 ± 0.7 <0.001
acrB 25.2 ± 1.1 <0.001
F. tularensis Schu S4 Avg p-value
wild-type 25.5 ± 1.9 --------
ΔacrA 41.7 ± 2.7 0.0001
ΔacrB 35.7 ± 4.3 0.001
For F. novicida RND efflux mutants, 15 ug Az discs were from Remel, while for F. tularensis Schu S4, 15 ug Az discs were from Fluka. The zone 
of inhibition was measured in mm.Ahmad et al. BMC Microbiology 2010, 10:123
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Another common mechanism of resistance to mac-
rolides is modification of the 23S rRNA. It has been
reported that F. tularensis LVS has a point mutation in
Domain V of the 23S rRNA, rendering it more resistant
to erythromycin than F. novicida or F. tularensis Schu S4
[38]. This modification could also explain the increased
resistance to Az in F. tularensis LVS. In addition, there are
methylases that can confer increased resistance by tar-
geted modification (methylation) of a specific adenine
residue of the 23S rRNA. There are some methylases that
have been identified as critical virulence factors for Fran-
cisella that might carry out this modification [39]. Some
methylases that are present in the genome of F. novicida
are either absent or are pseudogenes/nonfunctional genes
(such as FTT0010, FTT0770, FTT1430, FTT1719, and
FTT1735c) in F. tularensis Schu S4, potentially contribut-
ing to the different sensitivities to Az between the strains
[34]. Any potential role of these molecules in Az sensitiv-
ity or resistance in Francisella  has not yet been deter-
mined.
It has been suggested that Az attaches to the acidic LPS
on the outer membrane of gram-negative bacteria, allow-
ing the drug to penetrate through the outer membrane
Figure 5 Az inhibition of intracellular F. novicida mutants. A) 
J774A.1 and B) A549 cells were infected with various mutants at an MOI 
500. At 22 hours, the number of CFUs/ml recovered from F. novicida 
multidrug efflux mutants ftlC, tolC, acrA, and acrB and LPS O-antigen 
mutant wbtA decreased as Az concentrations increased and was near 
0 CFU/ml at 35 μg/ml Az (p-value < 0.005 for all Az treatments com-
pared to 0 μg/ml Az for each mutant). The recovery of mutant strains 
after Az treatments were significantly different from the wild-type F. 
novicida with a p-value < 0.05 (1.76 × 105 ± 6.36 × 103 CFU/ml in 
J774A.1 at 0 μg/ml Az which decreased to 0 CFU/ml at 5 μg/ml Az and 
1.80 × 105 ± 1.41 × 104 CFU/ml in A549 cells at 0 μg/ml Az which de-
creased to 0 CFU/ml at 25 μg/ml Az). J774A.1 cells had higher bacterial 
counts than A549 cells.
 
 
Figure 6 Antibiotic treatment of Francisella-infected G. mellonel-
la. High concentrations of antibiotics prolonged the survival of G. mel-
lonella infected with 3 × 106 CFU Francisella. Non-infected control 
groups consisted of no injection, PBS injection, 25 μg/ml Az injection, 
or 20 μg/ml ciprofloxacin injection. All non-infected controls had sim-
ilar high survival rates (data not shown for non-injected, 25 μg/ml Az 
injection, or 20 μg/ml ciprofloxacin injection). A) The infected control 
group received F. novicida injection, then PBS. A single dose of 25 μg/
ml Az, given 2 hours after bacterial inoculation, was effective when 
compared to the infected control (p-value = 0.004). Treatment with 20 
μg/ml ciprofloxacin prolonged the survival of the caterpillars com-
pared to the control (p-value < 0.01). B) The infected control group re-
ceived F. tularensis LVS injection, then PBS. A single dose of 25 μg/ml 
Az, given 2 hours after bacterial inoculation, was effective compared to 
the infected control (p-value < 0.001). Treatment with 20 μg/ml cipro-
floxacin prolonged the survival of the caterpillars compared to control 
(p-value < 0.01). For F. tularensis LVS and F. novicida infections, survival 
time was longer in Az treated groups compared to ciprofloxacin treat-
ed groups (p-value < 0.02).
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and enter the bacteria [40]. The wbt locus in Francisella,
which is responsible for the production of LPS O-antigen,
has been shown to be required for virulence [41]. In pub-
lished reports, the wbtA mutant in F. tularensis LVS dem-
onstrated a loss of the O-antigen and an inability to
replicate in mouse macrophages. F. novicida wbtA
mutants replicate normally and have only moderate sen-
sitivity to serum [42,43]. We tested F. novicida transpo-
son-insertion mutants wbtN, wbtE, wbtQ and  wbtA,
which are involved in the production of LPS, and found
that these mutants were less susceptible to Az. Mutations
of the LPS in the F. novicida transposon LPS O-antigen
mutants may alter the LPS region presumed to bind to
Az, resulting in a decreased amount of Az penetration
and increased resistance to Az. Our results support the
proposed role of LPS O-antigen in Az penetration into
gram-negative bacteria such as Francisella.
Az is a weak base that can remain inside host cells for a
longer time at a higher concentration than in the serum.
This occurs because the basic amine groups of Az neu-
tralize the lysosomal pH and prevent acidification of the
lysosome. This process causes the drug to become
trapped in the cell due to the positive charge. The drug is
slowly released from polymorphonuclear neutrophils,
allowing for a long half-life [8]. Az also concentrates in
macrophages, which suggested to us that it might be use-
ful as a potential treatment of intracellular pathogens
such as F. tularensis. J774A.1 mouse macrophage were
infected with F. philomiragia, F. novicida, and F. tularen-
sis LVS and treated with Az. It was determined that 5 μg/
ml Az was effective in eliminating intracellular F. philomi-
ragia, F. novicida, and even F. tularensis LVS infections in
J774A.1 cells. Although Type B strains are intrinsically
more resistant to macrolides, F. tularensis LVS CFUs
were eliminated below the Az MIC values for this strain.
We suggest that J774A.1 cells can sufficiently concentrate
Az so that the intramacrophage concentration of Az
exceeds the MIC. Thus, it may be that Az is effective
against LVS in vivo due to the concentration effect in
macrophages. A concentration of 25 μg/ml Az was found
to be effective against Francisella infections in A549 cells,
suggesting that these non-phagocytic cells may be less
able to concentrate the antibiotic intracellularly [22].
Az treatment has not been tested sufficiently in the
clinic to know if it can be used to treat tularemia infec-
tion. In one reported case, the patient's illness was fatal
after treatment by Az, trimethoprim-sulfamethoxazole,
streptomycin, and ceftriaxone of F. tularensis [44], sug-
gesting that the patient was extremely ill when treatment
was initiated. In another case, the patient's symptoms
decreased with a one day ceftriaxone treatment followed
by a 5 day Az treatment, but symptoms recurred after the
treatment was completed [45]. There have been several
reports of successful treatment with erythromycin, giving
credence to the sensitivity of Type A strains to the mac-
rolide class of antibiotics [46,47]. To test the in vivo effec-
tiveness of Az against Francisella  infections, we
employed the wax-moth caterpillar model [25]. The time-
course of infection of the caterpillars closely matched the
published report. We extended the published report by
demonstrating that wax-moth caterpillars can also be
infected by F. novicida. We demonstrated that a single
injection of Az increased the mean survival time of Fran-
cisella infected G. mellonella and is more effective than a
similar dose of ciprofloxacin. Within a host, macrolides,
including Az, inhibit the production of cytokines that
cause inflammation and prevent the accumulation of
neutrophils, which suggests immunomodulatory effects
separate from their antibacterial effects [48]. It has been
shown that after Francisella infection in mice, there is a
delayed response in the induction of host proinflamma-
tory cytokines and recruitment of inflammatory cells to
the site of infection, resulting in uncontrolled bacterial
replication [49]. G. mellonella, however, does not have a
similar immune response following Francisella infection.
Since the therapeutic efficacy of Az cannot be observed
in G. mellonella, future experiments will be conducted
using a mouse model. Our results demonstrate efficacy of
Az against multiple different Francisella strains and spe-
cies. In future work, we will extend the Az studies to
murine infections with the fully virulent strain, F. tularen-
sis Schu S4.
Conclusion
Az and other macrolide antibiotics may have a secondary
benefit to patients with pneumonic tularemia infection
since they also have immunomodulatory functions. Az
has been used to treat non-infectious respiratory diseases
such as diffuse panbronchiolitis (an inflammatory lung
disease) and has been shown to reduce cytokine
responses in the lungs thereby lessening the acute inflam-
matory response [48,50], even at sub-antimicrobial doses.
Az is also used in the long-term management of lung
transplant patients, including those with bronchiolitis
obliterans syndrome, a disease occasionally resulting
from the chronic immunological and inflammatory status
in some post-transplant lungs [51]. Pulmonary tularemia
often exhibits a robust pro-inflammatory response. If Az
proves to be effective against F. tularensis in vivo, it may
provide a dual therapeutic effect by also mitigating the
pro-inflammatory response. Thus, there may be addi-
tional non-antimicrobial benefits to the lung as a result of
using Az to treat pulmonary tularemia, which is often
complicated by robust pro-inflammatory responses.
The current established treatment protocol for tulare-
mia in children is ciprofloxacin [52]. However, ciprofloxa-
cin has the potential for significant side effects, including
liver toxicity, tendonitis and renal failure [40,53,54]. AzAhmad et al. BMC Microbiology 2010, 10:123
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(trade name: Zithromax) is commonly prescribed to
pediatric patients for ear infections and other common
gram-negative infections, with very safe outcomes [55].
With the finding that Az concentrates in macrophages
and is effective against Francisella  species (including
LVS) in vitro and in an in vivo infection model, we pro-
pose that further studies be done to establish the clinical
utility of Az against tularemia, as an alternative treat-
ment. In case of a deliberate tularemia infection of the
population, such as in a biological weapons attack, there
may be patients who can not tolerate the standard treat-
ment. Az could be tested either as a stand-alone therapy
or in combination with other chemotherapeutic agents.
Developing an alternate effective therapy to treat tulare-
mia in patients that do not tolerate ciprofloxacin well,
such as pediatric and elderly patients, will lead to safer
therapeutic options for physicians.
Methods
Antibiotics
The antibiotics investigated in this study were azithromy-
cin (Az) (Biochemika), gentamicin (ATCC), and cipro-
floxacin (Biochemika). Az was obtained as 15 μg discs
(Fluka # 68601 or Remel # R33105), and dry powder
(Fluka). Az was dissolved in distilled water and ciproflox-
acin was dissolved in 0.5 M HCl to appropriate concen-
tration. Gentamicin was obtained in solution at high
concentration (50 mg/ml, ATCC) and diluted in distilled
water.
Bacterial strains
The following reagents were obtained through the NIH
Biodefense and Emerging Infections Research Resources
Repository, NIAID, NIH: Francisella philomiragia
(ATCC #25015), F. tularensis holarctica Live Vaccine
Strain (LVS) FSC155 (#NR-646), F. novicida (#NR-13),
and F. novicida transposon insertion mutants (Table 7)
[56]. Bacteria were grown in trypticase soy broth supple-
mented with cysteine (TSB-C) for 24 or 48 (for LVS, a
slower growing organism) hours at 37°C in 5% CO2 to
approximately 1010 CFU/ml. F. tularensis tularensis strain
NIH B38 (B38) (ATCC 6223; BEI Resources # NR50,
deposited as the type strain for F. tularensis tularensis)
was grown on Chocolate II Agar plates (BD Biosciences)
at 37°C for 72 hours due to their extremely slow growth
rate. LPS mutants in wbtN, wbtE, wbtQ, and wbtA loci
were tested. RND efflux mutants in dsbB, acrA, acrB,
tolC, and ftlC were also tested (Table 7). F. tularensis Schu
S4 (CDC, Fort Collins, CO) and F. tularensis Schu S4
deletion mutants ΔdsbB,  ΔacrA, and ΔacrB  (21) were
t e s t e d  i n  a n  a p p r o v e d  b i o s a f e t y  l e v e l  3  l a b o r a t o r y  b y
trained personnel at the University of Virginia, Charlot-
tesville, VA (Table 7).
Cell culture
Mouse macrophage cells J774A.1 (ATCC #TIB-67) and
human lung epithelial cells A549 (ATCC #CCL-185) were
obtained from ATCC, Manassas, VA. J774A.1 cells were
grown in Dulbecco's Modified Eagle Medium (DMEM)
with 10% fetal bovine serum and passed every 3 days in a
1:3 dilution following manufacturers' instructions. A549
cells were grown in Ham's F-12 with 10% fetal bovine
serum and passed every 3 days in a 1:3 dilution.
Disc inhibition assay
Kirby-Bauer disc inhibition assay protocol was followed
[57]. 100 μl of overnight bacterial cultures were spread on
Chocolate II agar and Schu S4 strains were spread on
Mueller-Hinton agar plate with three discs each contain-
ing 15 μg Az placed in a triangle and incubated based on
length of time for bacterial growth to be seen on the
plate: 24 (for F. novicida, F. philomiragia, and F. tularensis
Schu S4), 48 (for F. tularensis LVS), and 72 hours (for F.
tularensis NIH B38) at 37°C in 5% CO2. The diameter of
the zone of inhibition including the 6 mm disc was mea-
sured (in mm) with three independent measurements for
each zone (n = 9). Inhibition was defined as the area of no
bacterial growth around the discs. A reading of 6 mm
indicates no inhibition [57].
Minimal inhibitory concentration (MIC)
Assays were performed with small modification following
published protocols [58]. The MIC for F. novicida, F. phi-
lomiragia, F. tularensis LVS, related F. novicida mutants,
F. tularensis Schu S4, and related F. tularensis Schu S4
mutants were determined in TSB-C media by antibiotic
dilution in triplicates. The broth was then inoculated
with 105 CFU/ml per strain. Concentration of the antibi-
otics ranged from 1 mg/ml to 0.0001 μg/ml. The MIC was
read at optical density 600 nm after 24 hours (for F. philo-
miragia, F. novicida, and F. tularensis Schu S4) and after
48 hours (for F. tularensis LVS) and was defined as the
lowest concentration of antibiotic with no visible growth.
Data analysis and statistics
Data were analyzed using the following equation and
GraphPad Prism 4 (GraphPad Software Inc., San Diego,
CA) [23].
Y corresponds to bacterial mortality (% OD, where zero
drug = 100%) at a given antibiotic concentration (μg/ml),
with X being the logarithm of that concentration (log μg/
ml). In the equation, "Top" and "Bottom" refer to the
upper and lower boundaries, and were constrained to val-
ues <100% and >0%, respectively. EC50 values were deter-
mined by fitting the data from the antimicrobial assays to
Y Bottom Top-Bottom LogEC X Hill Slope =+ + − (( ) /( ^[( )* ]). 11 0 50Ahmad et al. BMC Microbiology 2010, 10:123
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a standard sigmoidal dose-response curve (Equation 1)
with a Hill slope of 1. Control samples with no antibiotic
are plotted as 10^-4 μg/ml for graphing purposes. Errors
were reported based on the standard deviation from the
mean of the Log EC50 values. Student's T-test was used to
determine whether points were statistically different,
using a two tailed test assuming normal distribution.
Cell infection with Francisella strains
J774A.1 cells and A549 cells were plated (105/well) in a
96-well plate and infected with either F. novicida, F. philo-
miragia, F. tularensis LVS, or F. novicida transposon
mutants at MOI 500 for 2 hour incubation. Extracellular
bacteria were removed by washing cell wells twice with
DMEM for J774A.1 cells or Ham's F-12 for A549 cells.
After Francisella  infection and removal of extracellular
bacterium, cells were incubated with 50 μg/ml gentami-
cin for 1 hour to eliminate extracellular bacterium but
which does not affect intracellular bacteria. Cells were
washed with media twice and incubated with Az in the
media at final concentrations of 0, 0.1, 5, 15, 25, and 35
μg/ml for 0 or 22 hours at 37°C.
Quantification of intracellular Francisella bacteria
After exposure of cells to Francisella and antibiotics, the
numbers of intracellular bacteria were determined. At 0
and 22 hours, the samples were washed twice with PBS.
Sterile deionized water was used to lyse cells. Aliquots of
cells and cell-associated bacteria were serially diluted
onto chocolate agar plates, incubated at 37°C and 5% CO2
for 1 or 2 days and the CFU were counted.
Quantification of cellular apoptosis
After exposure of cells to Francisella and antibiotics, the
numbers of cell-associated bacteria were determined, the
CytoTox-96®  Non-radioactive Cytotoxicity Assay (Pro-
mega) was used to quantitatively measure lactate dehy-
Table 7: F. novicida and F. tularensis subsp. tularensis Schu S4 mutants used.
Mutant abbreviation Mutant name Gene
wbtN tnfn1_pw060420p04q142 wbtN FTN_1422
wbtE tnfn1_pw060328p03q164 wbtE FTN_1426
wbtQ tnfn1_pw060419p04q158 wbtQ FTN_1430
wbtA tnfn1_pw060419p03q166 wbtA FTN_1431
tolC tnfn1_pw060419p03q111 tolC FTN_1703
tolC* tnfn1_pw060328p03q137 tolC FTN_1703
ftlC tnfn1_pw060418p04q166 Hypothetical protein FTN_0779
dsbB tnfn1_pw060323p05q173 dsbB FTN_1608
acrA tnfn1_pw060328p06q117 Membrane fusion protein FTN_1609
acrA* tnfn1_pw060419p03q103 Membrane fusion protein FTN_1609
acrB tnfn1_pw060323p02q131 RND efflux transporter, AcrB/AcrD/AcrF family FTN_1610
acrB* tnfn1_pw060418p04q118 RND efflux transporter, AcrB/AcrD/AcrF family FTN_1610
ΔacrB BJM1032 Schu S4 ΔacrB [16] (FTT0105c)
ΔacrA BJM1040 Schu S4 ΔacrA [16] (FTT0106c)
(*= these mutants were tested, but data is not shown as it was the same as the first mutant).Ahmad et al. BMC Microbiology 2010, 10:123
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drogenase (LDH) release at 22 hours, following
m a n u f a c t u r e r s '  i n s t r u c t i o n s .  A b s o r b a n c e  v a l u e s  w e r e
recorded at OD 490 nm by spectrophotometer (μQuant,
BioTek). Background noise values were subtracted from
sample readings. Determine % cell death using formula:
Galleria mellonella exposure to Francisella strains and 
treatment with antibiotics
Galleria mellonella was obtained at the larval stages from
Vanderhorst Wholesale (Saint Marys, OH). 10 caterpil-
lars with a weight of 0.30-0.35 g were used for each group.
Injection area was cleaned with water and a 10 μl Hamil-
ton syringe was used to inject 10 μl of 3 × 106 CFU/ml of
either F. novicida or F. tularensis LVS into the hemocoel
of each caterpillar via the last left proleg and incubated at
37°C for 2 hours [25]. Caterpillars were then injected with
10 μl of either PBS, 25 μg/ml Az, or 20 μg/ml ciprofloxa-
cin in the last right proleg. Control caterpillars were
either not injected or injected with only PBS, azithromy-
cin, or ciprofloxacin. Caterpillar groups were incubated
at 37°C and scored daily for color change or death.
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